SAFETY AND EFFICACY RESULTS FROM A PHASE 1/1B STUDY OF INTRATUMORAL MK-4621, A RETINOIC ACID-INDUCIBLE GENE I (RIG-I) AGONIST, PLUS INTRAVENOUS PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0

作者：

Moreno, Victor ^{[1
]}

Gaudy-Marqueste, Caroline ^{[2
]}

Wermke, Martin ^{[3
]}

Italiano, Antoine ^{[4
]}

Romano, Emanuela ^{[5
]}

Marabelle, Aurelien ^{[6
]}

Connors, Emilee ^{[7
]}

Zhou, Heng ^{[7
]}

Dobrenkov, Konstantin ^{[7
]}

Chartash, Elliot ^{[7
]}

Calvo, Emiliano ^{[8
]}

Calvo Aller, Emiliano ^{[8
]}

机构：

[1] Hosp Univ Fdn Jimenez, ISTART Madrid FJD, Madrid, Spain

[2] Timones Hosp, CEPCM CLIP2, Marseille, France

[3] Univ Klinikum Carl Gustav Carus, Dresden, Germany

[4] Inst Bergonie, Bordeaux, France

[5] Inst Curie, Paris, France

[6] Inst Gustave Roussy, Villejuif, France

[7] Merck & Co Inc, Kenilworth, NJ USA

[8] Ctr Integral Onco, START Madrid CIOCC, Madrid, Spain

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷

关键词：

D O I：

10.1136/jitc-2020-SITC2020.0794

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

794

引用

页码：A474 / A475

页数：2

共 50 条

[31] A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study
Ann W. Silk
Steven J. O’Day
Howard L. Kaufman
Jennifer Bryan
Jacqueline T. Norrell
Casey Imbergamo
Daniella Portal
Edwin Zambrano-Acosta
Marisa Palmeri
Seymour Fein
Cai Wu
Leslie Guerreiro
Daniel Medina
Praveen K. Bommareddy
Andrew Zloza
Bernard A. Fox
Carmen Ballesteros-Merino
Yixin Ren
Darren Shafren
Mark Grose
Joshua A. Vieth
Janice M. Mehnert
Cancer Immunology, Immunotherapy, 2023, 72 : 1405 - 1415
[32] Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study.
Silk, Ann W.
O'Day, Steven J.
Kaufman, Howard L.
Bryan, Jennifer
Norrell, Jacqueline T.
Imbergamo, Casey
Portal, Daniella
Zambrano-Acosta, Edwin
Palmeri, Marisa
Fein, Seymour
Wu, Cai
Guerreiro, Leslie
Medina, Daniel
Bommareddy, Praveen K.
Zloza, Andrew
Fox, Bernard A.
Ballesteros-Merino, Carmen
Shafren, Darren
Grose, Mark
Vieth, Joshua A.
Mehnert, Janice M.
CANCER RESEARCH, 2021, 81 (13)
[33] Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial
Tolcher, Anthony W.
Meyers, Michael L.
Gabrilovich, Dmitry
Wang, Fang
Trepel, Jane
Lee, Min-Jung
Schmitt, Emmett
Quaranto, Christine
Sankoh, Serap
Tamang, David
Ordentlich, Peter
CANCER RESEARCH, 2018, 78 (13)
[34] Pharmacodynamic, safety, and efficacy results of a phase I/II trial of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab (PEM) (Keynote A10) in patients with advanced solid tumors.
Thomas, Jacob Stephen
El-Khoueiry, Anthony B.
Walters, Ian B.
Azad, Nilofer Saba
Bender, Lewis H.
Hanna, Diana L.
Whalen, Giles Francis
Olszanski, Anthony J.
Siu, Lillian L.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[35] An open-label, multicenter, phase 1b/2 Study of E7386 (Wnt/ß-catenin pathway inhibitor) plus pembrolizumab in patients with pretreated advanced solid tumors
Yoshino, Takayuki
Ikeda, Masafumi
Finn, Richard S.
Evans, Thomas R. Jeffry
Weng, Lidong
Saito, Kenichi
Mody, Kalgi
Tamai, Toshiyuki
Paoletti, Costanza
Iwasa, Satoru
CANCER RESEARCH, 2022, 82 (12)
[36] First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
Postel-Vinay, Sophie
Lam, Vincent K.
Ros, Willeke
Bauer, Todd M.
Hansen, Aaron R.
Cho, Daniel C.
Stephen Hodi, F.
Schellens, Jan H. M.
Litton, Jennifer K.
Aspeslagh, Sandrine
Autio, Karen A.
Opdam, Frans L.
McKean, Meredith
Somaiah, Neeta
Champiat, Stephane
Altan, Mehmet
Spreafico, Anna
Rahma, Osama
Paul, Elaine M.
Ahlers, Christoph M.
Zhou, Helen
Struemper, Herbert
Gorman, Shelby A.
Watmuff, Maura
Yablonski, Kaitlin M.
Yanamandra, Niranjan
Chisamore, Michael J.
Schmidt, Emmett, V
Hoos, Axel
Marabelle, Aurelien
Weber, Jeffrey S.
Heymach, John, V
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (03)
[37] Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: Preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or metastatic solid tumors
Janku, Filip
Birrer, Michael
Richardson, Debra
Chu, Christina
Goel, Sanjay
Su, Ying
Matin, Bahar
Kuida, Keisuke
Ruiz-Soto, Rodrigo
Hamilton, Erika Paige
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
[38] Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors
Siu, Lillian L.
Gil-Martin, Marta
Cho, Byoung Chul
Perets, Ruth
Hilton, John
Geva, Ravit
Lugowska, Iwona
Gutierrez, Martin
Bonomi, Marcelo
Dziadziuszko, Rafal
Rasco, Drew
Ben-Ami, Eytan
Rodriguez, Cristina P.
Siddiqi, Shabana
Myer, Nicole
Suttner, Leah
Wilson, Douglas
Akala, Ombololaji O.
de Miguel, Maria
CANCER RESEARCH, 2024, 84 (07)
[39] Safety, efficacy, and pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a phase 2 collaboration study
Lim, Young-Suk
Hui, Aric J.
Jang, Jeong-Won
Tak, Won-Young
Ahn, Sang Hoon
Jang, Byoung Kuk
Tsang, Tak Yin Owen
Kim, Won
Yang, Jenny
Chen, Diana
McDonald, Circe
Zhang, Liao
Gaggar, Anuj
Gao, Bing
Byun, Kwan Soo
Lee, Kwan Sik
Yim, Hyung Joon
Chan, Henry L. Y.
JOURNAL OF HEPATOLOGY, 2021, 75 : S757 - S757
[40] The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
Martinez-Lopez, Joaquin
Mustjoki, Satu
Porkka, Kimmo
Klisovic, Rebecca B.
Wolf, Dominik
Busque, Lambert
Hernandez-Boluda, Juan Carlos
Swanink, Rene
Martin Regueira, Patricia
Lipton, Jeffrey H.
LEUKEMIA & LYMPHOMA, 2021, 62 (08) : 2040 - 2043

← 1 2 3 4 5 →